Home > Publications database > Lack of detectable HPV18 antibodies in 14% of quadrivalent vaccinees in a longitudinal cohort study. > print

001     292299
005     20250321101759.0
024 7 _ |a 10.1038/s41541-024-00941-w
|2 doi
024 7 _ |a pmid:39138224
|2 pmid
024 7 _ |a altmetric:166277236
|2 altmetric
037 _ _ |a DKFZ-2024-01659
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Gray, Penelope
|0 0000-0001-9065-4734
|b 0
245 _ _ |a Lack of detectable HPV18 antibodies in 14% of quadrivalent vaccinees in a longitudinal cohort study.
260 _ _ |a [London]
|c 2024
|b Nature Publishing Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1723639538_8152
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:D335#
520 _ _ |a Although HPV vaccines are highly efficacious, a notable proportion of quadrivalent vaccinees are HPV18 seronegative post-vaccination. We have investigated this findings' validity by comparing vaccine-induced antibody responses using two different immunoassays. 6558 16-17-year-old females participated in the FUTURE II (NCT00092534) and PATRICIA (NCT00122681) trials in 2002-2004. Both the quadrivalent and bivalent vaccine recipients (QVR and BVR) received three doses. Twelve-year follow-up for 648 vaccinees was conducted by the Finnish Maternity Cohort. The presence of neutralising and binding HPV antibodies was analysed via HPV pseudovirion-based neutralisation and pseudovirion-binding assays. Four percent and 14.3% of the QVRs were seronegative for neutralising and binding antibodies to HPV16 and HPV18, respectively. No BVRs were HPV16/18 seronegative post-vaccination. The antibody titres were strongly correlated between the assays, Pearson's correlation coefficient, r[HPV16] = 0.92 and 0.85, and r[HPV18] = 0.91 and 0.86 among the QVRs and BVRs respectively. Fourteen percent of QVRs lacked detectable HPV18 antibodies in long-term follow-up.
536 _ _ |a 314 - Immunologie und Krebs (POF4-314)
|0 G:(DE-HGF)POF4-314
|c POF4-314
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
700 1 _ |a Mariz, Filipe Colaço
|0 0000-0001-6624-4524
|b 1
|e First author
700 1 _ |a Eklund, Carina
|b 2
700 1 _ |a Eriksson, Tiina
|b 3
700 1 _ |a Faust, Helena
|b 4
700 1 _ |a Kann, Hanna
|b 5
700 1 _ |a Müller, Martin
|0 P:(DE-He78)4cbf38280ce272e37f96081b070dd46a
|b 6
|u dkfz
700 1 _ |a Paavonen, Jorma
|b 7
700 1 _ |a Pimenoff, Ville N
|0 0000-0002-0813-7031
|b 8
700 1 _ |a Sehr, Peter
|b 9
700 1 _ |a Surcel, Heljä-Marja
|b 10
700 1 _ |a Dillner, Joakim
|b 11
700 1 _ |a Waterboer, Tim
|0 P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30
|b 12
|u dkfz
700 1 _ |a Lehtinen, Matti
|b 13
773 _ _ |a 10.1038/s41541-024-00941-w
|g Vol. 9, no. 1, p. 146
|0 PERI:(DE-600)2882262-6
|n 1
|p 146
|t npj vaccines
|v 9
|y 2024
|x 2059-0105
856 4 _ |u https://inrepo02.dkfz.de/record/292299/files/s41541-024-00941-w.pdf
856 4 _ |u https://inrepo02.dkfz.de/record/292299/files/s41541-024-00941-w.pdf?subformat=pdfa
|x pdfa
909 C O |o oai:inrepo02.dkfz.de:292299
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 0000-0001-6624-4524
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)4cbf38280ce272e37f96081b070dd46a
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-314
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Immunologie und Krebs
|x 0
914 1 _ |y 2024
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NPJ VACCINES : 2022
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-04-12T15:11:19Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-04-12T15:11:19Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-04-12T15:11:19Z
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2023-04-12T15:11:19Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-08-24
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-24
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b NPJ VACCINES : 2022
|d 2023-08-24
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-08-24
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-08-24
920 0 _ |0 I:(DE-He78)D335-20160331
|k D335
|l Tumorvirus-spez. Vakzinierungsstrategie
|x 0
920 1 _ |0 I:(DE-He78)D335-20160331
|k D335
|l Tumorvirus-spez. Vakzinierungsstrategie
|x 0
920 1 _ |0 I:(DE-He78)D320-20160331
|k D320
|l Infektionen und Krebs-Epidemiologie
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)D335-20160331
980 _ _ |a I:(DE-He78)D320-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21